ArticleFrontiers in public health2025
Extemporaneous dermatological compounding in hospital pharmacies, Northwest Ethiopia.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmaceutical profile and prescribing practices in compounding pharmacies in Brazil: a cross-sectional study.Frontiers in pharmacology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dermatological problems are among the leading causes of hospital visits in Ethiopia. Extemporaneous compounded products are currently used by many patients with different disorders. The aim of the study was to evaluate the most commonly prescribed extemporaneously compounded products compounding practice and applicability of compounding guidelines at five randomly selected hospitals in Northwest Ethiopia. Methods: A hospital-based multicenter descriptive cross-sectional study was conducted by retrospectively analyzing prescription records for dermatological compounding from January to April 2023. A total of 423 prescriptions from hospital pharmacies were systematically selected. Data related to skin condition patterns, product selection, and dosage form types were extracted using a semi-structured data extraction tool and analyzed using SPSS version 25.0 at a significance level of 5%. Results: A total of 423 prescriptions containing dermatological products for compounding were analyzed. Most patients were female (82.1%) and aged 30-64 years (46.3%). Melasma (82.9%), acne vulgaris (68.6%), acute dermatitis (63.27%), and Rosacea (61.54%) were the four top dermatological diseases for which compounding preparations were prescribed. More than half of the prescriptions (56.26%) contained a combination of two drugs. Most compounded dosage form was semisolid preparations (95.98%), while the remaining 17 (4.02%) were liquids. Salicylic acid (35.39%) was the most frequently prescribed active ingredient, followed by Clobetasone (13.03%) and Betamethasone (10.01%). Vaseline (47.62%) and Nivea cream (44.3%) were the most commonly used excipients for compound preparations. Hydroquinone (4%) with Nivea cream (30gm) (17.0%), followed by salicylic acid (5%) + Betamethasone (75 g) + Vaseline (20 g) (10.6%) were the most commonly prescribed dermatological formulations. Conclusion: Dermatological disease is more prevalent in the study area. and extemporaneous compounding is a common element of pharmaceutical care. Extemporaneous and topical semisolid preparations containing two or more active ingredients are the most widely compounded and prescribed products. This study suggests the application of good manufacturing practices and componding guidelines for extemporaneous compounding of dermatological formulations to ensure efficacy, quality, and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.